× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En Fr

Our approach

adjuvant therapies

anticoagulant 2

anticoagulant, curative dose 2

anticoagulant, prophylactic dose 4

heparin at therapeutic dose 3

hydrogen-oxygen nebulizer

hyperbaric oxygen

pulmonary rehabilitation

anti-inflammatoty and immuno-therapy

acalabrutinib 2

anti-inflammatory therapies 1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs 5

sodium aescinate

corticosteroids 8

dexamethasone 2

Hydrocortisone 3

inhaled steroids

low-dose corticosteroids

methylprednisolone 2

Immunostimulants drugs

anti-PD-1 antibody

convalescent plasma treatment 18

immunoglobulin therapy

inactivated mycobacterium vaccine

interferon / TFF2 1

SNG001 inhaled interferon beta 1

neutralizing antibody 2

bamlanivimab (LY-CoV555)

Immunosuppressants drugs

anti-interleukin-6

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

baricitinib plus remdesivir 1

Polyinosinic-Polycytidylic Acid

5-alpha-reductase inhibitors

antiviral and associated therapy

ASC09/ritonavir

baloxavir marboxil 1

chloroquine and derivatives 2

hydroxychloroquine 41

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

hydroxychloroquine plus macrolides 9

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 6

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b 1

oseltamivir plus chloroquin

Renin-angiotensin-system-acting agents 8

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

discontinuation of ACEI/ARB 1

RAS blocker withdrawal

sofosbuvir and daclatasvir

tranexamic acid

umifenovir (arbidol) 4

prone positioning

alpha lipoic acid 1

BLD-2660 (calpain inhibitor)

calcium channel blocker

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

DPP-4 inhibitor

kinin-kallikrein inhibitors

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

proton pump inhibitors (PPI) 6

PUL-042 inhalation solution

zinc plus hydroxychloroquine

BCG vaccination

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy -